Skip to content

Guardian Pharmacy SErvices Inc

GRDN

Latest QuantConomy context for GRDN: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NYSE
Recent signals
3
SEC filings
20
Asset profile

Guardian Pharmacy SErvices Inc

QuantConomy has a structured record for GRDN. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
GRDN
Name
Guardian Pharmacy SErvices Inc
Coverage
3 market/data records
Sources
alphavantage alpaca fmp sec nasdaq
Latest signal rows

Recent signals for GRDN

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
earnings release
neutral
40
Jan 13, 12:00 AM GRDN filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-13. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
earnings release
neutral
40
Mar 11, 12:00 AM GRDN filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-11. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
executive change
neutral
85
Jun 22, 08:40 PM GRDN filed 8-K: Director or Officer Changes, Regulation FD Disclosure - 2 material events - [very strong neutral signal]

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

Market coverage

Market Exchange Source Asset record
GRDN NYSE alphavantage Guardian Pharmacy Services Inc
GRDN NYSE alpaca Guardian Pharmacy Services, Inc.
GRDN NYSE fmp Guardian Pharmacy Services, Inc.

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
0
Rows
20
Date Insider Role Type Shares Price Value Filing
May 5, 2026 LEWIS RANDALL J Director grant 4,028 $0.00 $0 4 on EDGAR
May 5, 2026 Patchett Mary Sue Director grant 4,028 $0.00 $0 4 on EDGAR
May 5, 2026 COSLER STEVEN D Director grant 4,028 $0.00 $0 4 on EDGAR
Weir Robert See Remarks 3 on EDGAR
Crisafulli Chris See Remarks 3 on EDGAR
Martin David Norman See Remarks 3 on EDGAR
Tuch Jeffrey See Remarks 3 on EDGAR
Eakins Richard Senior Vice President, Sales 3 on EDGAR
Mudd William Franklin Senior Vice President, Finance 3 on EDGAR
Towns Douglas See Remarks 3 on EDGAR
Mar 28, 2026 Ackerman John Director exercise 1,413,939 4 on EDGAR
Mar 28, 2026 Bindley Capital Partners I, LLC 10% owner exercise 6,100,175 4 on EDGAR
Mar 28, 2026 BINDLEY WILLIAM E Director, 10% owner exercise 6,100,175 4 on EDGAR
Mar 28, 2026 Cardinal Equity Fund, L.P. Insider exercise 471,057 4 on EDGAR
Mar 28, 2026 Forbes Kendall See Remarks exercise 608,570 4 on EDGAR
Mar 28, 2026 Pharmacy Investors, LLC Insider exercise 1,413,939 4 on EDGAR
Mar 28, 2026 Morris David K See Remarks exercise 641,869 4 on EDGAR
Mar 28, 2026 Salentine Thomas J Jr Director, 10% owner exercise 6,100,175 4 on EDGAR
Mar 28, 2026 Burke Fred See Remarks exercise 1,298,826 4 on EDGAR
Mar 20, 2026 Cardinal Equity Fund, L.P. Insider sale 275,728 $29.68 $8,184,296 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query GRDN context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access